Browsing Tag
Pharma acquisition news
231 posts
Cycle Pharmaceuticals proposes $466m acquisition of Vanda Pharmaceuticals
In a significant development within the pharmaceutical industry, UK-based Cycle Pharmaceuticals has offered to acquire Nasdaq-listed Vanda Pharmaceuticals…
GSK acquires Elsie Biotechnologies for up to $50m to enhance oligonucleotide therapeutics
GSK plc (LSE/NYSE: GSK), a global healthcare leader, has completed the acquisition of Elsie Biotechnologies, a private biotechnology…
AstraZeneca acquisition of Fusion Pharmaceuticals receives shareholder approval
In a significant step towards finalizing the acquisition, Fusion Pharmaceuticals Inc.’s shareholders have overwhelmingly voted in favor of…
Merck to acquire EyeBio in $3bn deal to expand ophthalmology pipeline
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has announced a definitive…
Johnson & Johnson strikes $1.2bn deal with Numab Therapeutics for atopic dermatitis candidate
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive…
Johnson & Johnson to acquire Proteologix in $850m deal to enhance immunology portfolio
Johnson & Johnson (NYSE: JNJ) has entered into a definitive agreement to acquire Proteologix, Inc., a leading biotechnology…
Novartis to expand oncology portfolio with acquisition of Mariana Oncology
Novartis has announced a significant move in the oncology sector with its agreement to acquire Mariana Oncology, a…
ONO Pharmaceutical to acquire Deciphera Pharmaceuticals in $2.4bn deal
ONO Pharmaceutical, Co., Ltd., has entered into a definitive agreement to acquire all outstanding shares of Deciphera Pharmaceuticals,…
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9bn in strategic expansion
In a major development in the biotechnology industry, Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and Alpine Immune Sciences, Inc.…
Gilead Sciences completes $4.3bn acquisition of CymaBay Therapeutics to enhance liver disease portfolio
Gilead Sciences, Inc. (Nasdaq: GILD) has officially announced the successful acquisition of CymaBay Therapeutics, Inc. (Nasdaq: CBAY) for…